2/4
08:00 am
rvph
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Medium
Report
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/30
08:00 am
rvph
Reviva to Participate in the 2025 BIO CEO & Investor Conference
Low
Report
Reviva to Participate in the 2025 BIO CEO & Investor Conference
1/22
08:14 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its price target lowered by analysts at HC Wainwright from $14.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its price target lowered by analysts at HC Wainwright from $14.00 to $11.00. They now have a "buy" rating on the stock.
1/21
08:02 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
High
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/11
05:38 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
1/10
11:57 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock.
Medium
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock.
1/10
08:04 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $7.00 price target on the stock.
Medium
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $7.00 price target on the stock.
1/7
08:35 am
rvph
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit [Yahoo! Finance]
Low
Report
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit [Yahoo! Finance]
1/7
08:00 am
rvph
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
Low
Report
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
12/16
10:25 pm
rvph
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
High
Report
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
12/16
05:18 pm
rvph
Reviva Announces Proposed Public Offering
High
Report
Reviva Announces Proposed Public Offering
12/16
08:07 am
rvph
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia [Yahoo! Finance]
High
Report
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia [Yahoo! Finance]
12/16
08:00 am
rvph
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
High
Report
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia